Lexaria Bioscience (LEXX) Cash from Financing Activities (2010 - 2026)

Lexaria Bioscience has disclosed Cash from Financing Activities across 17 years of filings, most recently posting $3.0 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $3.0 million, up 25873.16% year-over-year; the trailing twelve-month figure through Feb 2026 was $8.2 million (down 12.69% YoY), and the FY2025 annual result was $6.0 million, down 41.39% from the prior year.
• Cash from Financing Activities came in at $3.0 million for Q1 2026 at Lexaria Bioscience, down from $3.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $5.0 million in Q2 2024 to a low of -$121687.0 in Q3 2023.
• The 5-year median for Cash from Financing Activities is $1.7 million (2023), against an average of $1.9 million.
• Across the five-year window, Cash from Financing Activities plunged 986.01% in 2023 and jumped 25873.16% in 2026, its largest moves.
• Lexaria Bioscience's Cash from Financing Activities stood at -$11205.0 in 2022, then jumped by 16337.13% to $1.8 million in 2023, then surged by 138.84% to $4.3 million in 2024, then slipped by 20.05% to $3.5 million in 2025, then decreased by 12.38% to $3.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.0 million (Q1 2026), $3.5 million (Q4 2025), and $1.7 million (Q2 2025), per Business Quant data.